

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|---|--|-----------|---|
| (51) International Patent Classification ⁶ : C12N 15/12, 15/81, 15/53, C07K 14/78, A61K 38/39 | | A1 | (11) International Publication Number: WO 98/18918 |
| | | | (43) International Publication Date: 7 May 1998 (07.05.98) |
| (21) International Application Number: PCT/AU97/00721 | | | (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). |
| (22) International Filing Date: 29 October 1997 (29.10.97) | | | |
| (30) Priority Data: PO 3310 29 October 1996 (29.10.96) AU PO 4306 19 December 1996 (19.12.96) AU | | | |
| (71) Applicant (for all designated States except US): COMMON-WEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION [AU/AU]; Limestone Avenue, Campbell, ACT 2601 (AU). | | | |
| (72) Inventors; and (75) Inventors/Applicants (for US only): VAUGHAN, Paul, Richard [AU/AU]; 2/319 Jells Road, Wheelers Hill, VIC 3150 (AU). GALANIS, Maria [AU/AU]; 5 Rowitta Drive, Glen Waverley, VIC 3150 (AU). RAMSHAW, John, Alan, Maurice [AU/AU]; 31 Pleasant Street, Pascoe Vale, VIC 3044 (AU). WERKMEISTER, Jerome, Anthony [AU/AU]; 2 Wanawong Crescent, Camberwell, VIC 3124 (AU). | | | |
| (74) Agent: F. B. RICE & CO.; 28A Montague Street, Balmain, NSW 2041 (AU). | | | Published <i>With international search report.</i> |
| (54) Title: STABLE EXPRESSION OF TRIPLE HELICAL PROTEINS | | | |
| (57) Abstract <p>The invention relates to a method of producing a hydroxylated triple helical protein in yeast comprising the steps of: introducing to a suitable yeast host cell a first nucleotide sequence encoding P4H α subunit, a second nucleotide sequence encoding P4H β subunit and one or more product-encoding nucleotide sequences which encode(s) a polypeptide(s) or peptide(s) which, when hydroxylated, form the said hydroxylated triple helical protein, each of said first, second and product-encoding nucleotide sequences being operably linked to promoter sequences; and culturing said yeast host cell under conditions suitable to achieve expression of said first, second and product-encoding nucleotide sequences to thereby produce said hydroxylated triple helical protein; wherein said method is characterised in that the step of introducing the first, second and product-encoding nucleotide sequences results in the said first, second and product-encoding nucleotide sequences, together with their respective operably linked promoter sequences, being borne on one or more replicable DNA molecules that are stably retained and segregated by said yeast host cell during said step of culturing. Transformed yeast host cells and triple helical proteins produced in accordance with the method of the invention are also claimed.</p> | | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|---------------------|----|-----------------------|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | | Republic of Macedonia | TR | Turkey |
| BG | Bulgaria | HU | Hungary | ML | Mali | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MN | Mongolia | UA | Ukraine |
| BR | Brazil | IL | Israel | MR | Mauritania | UG | Uganda |
| BY | Belarus | IS | Iceland | MW | Malawi | US | United States of America |
| CA | Canada | IT | Italy | MX | Mexico | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NE | Niger | VN | Viet Nam |
| CG | Congo | KE | Kenya | NL | Netherlands | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NO | Norway | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's | NZ | New Zealand | | |
| CM | Cameroon | | Republic of Korea | PL | Poland | | |
| CN | China | KR | Republic of Korea | PT | Portugal | | |
| CU | Cuba | KZ | Kazakstan | RO | Romania | | |
| CZ | Czech Republic | LC | Saint Lucia | RU | Russian Federation | | |
| DE | Germany | LI | Liechtenstein | SD | Sudan | | |
| DK | Denmark | LK | Sri Lanka | SE | Sweden | | |
| EE | Estonia | LR | Liberia | SG | Singapore | | |

STABLE EXPRESSION OF TRIPLE HELICAL PROTEINS

Field of the Invention:

This invention relates to the production of hydroxylated triple helical proteins such as natural and synthetic collagens, natural and synthetic collagen fragments, and natural and synthetic collagen-like proteins, by recombinant DNA technology. In particular, the invention relates to a method for producing hydroxylated triple helical proteins in yeast host cells by introducing to a suitable yeast host cell, DNA sequences encoding the triple helical protein as well as prolyl 4-hydroxylase (P4H), in a manner wherein the introduced DNA sequences are stably retained and segregated by the yeast host cells.

Background of the Invention:

The collagen family of proteins represents the most abundant protein in mammals, forming the major fibrous component of, for example, skin, bone, tendon, cartilage and blood vessels. Each collagen protein consists of three polypeptide chains (alpha chains) characterised by a $(\text{Gly-X-Y})_n$ repeating sequence, which are folded into a triple helical protein conformation. Type I collagen (typically found in skin, tendon, bone and cornea) consists of two types of polypeptide chain termed $\alpha 1(\text{I})$ and $\alpha 2(\text{I})$ [i.e. $\alpha 1(\text{I})_2\alpha 2(\text{I})$], while other collagen types such as Type II [$\alpha 1(\text{II})_3$] and Type III [$\alpha 1(\text{III})_3$] have three identical polypeptide chains. These collagen proteins spontaneously aggregate to form fibrils which are incorporated into the extracellular matrix where, in mature tissue, they have a structural role and, in developing tissue, they have a directive role. The collagen fibrils, after cross-linking, are highly insoluble and have great tensile strength.

The ability of collagen to form insoluble fibrils makes them attractive for numerous medical applications including bioimplant production, soft tissue augmentation and wound/burn dressings. To date, most collagens approved for these applications have been sourced from animal sources, primarily bovine. While such animal-sourced collagens have been successful, there is some concern that their use risks serious immunogenicity problems and transmission of infective diseases and spongiform encephalopathies (e.g. bovine spongiform encephalopathy (BSE)). Accordingly, there is significant interest in the development of methods of

production of collagens or collagen fragments by recombinant DNA technology. Further, the use of recombinant DNA technology is desirable in that it allows for the potential production of synthetic collagens and collagen fragments which may include, for example, exogenous biologically active domains (i.e. to provide additional protein function) and other useful characteristics (e.g. improved biocompatibility and stability).

The *in vivo* biosynthesis of collagen proteins is a complex process involving many post translational events. A key event is the hydroxylation by the enzyme prolyl 4-hydroxylase (P4H) of prolyl residues in the Y-position of the repeating (Gly-X-Y)_n sequences to 4-hydroxyproline. This hydroxylation has been found to be beneficial for nucleation of folding of triple helical proteins. For collagens, it is essential for stability at body temperature. Accordingly, the development of a commercially viable method for the production of recombinant collagen requires co-expression of P4H with the alpha chains. For mammalian host cells, co-expression of P4H will occur autonomously since these cells should naturally express P4H. However, for yeast host cells, which for reasons of cost, ease and efficiency are more attractive for expression of recombinant eukaryotic proteins, transformation with DNA sequences encoding P4H will also be required. Since P4H consists of α and β subunits of about 60 kDa and 60 kDa, yeast host cells for expression of recombinant collagen will require co-transformation with at least three exogenous DNA sequences (i.e., encoding an alpha chain, P4H α subunit and P4H β subunit) and stability problems would therefore be expected if cloned on three separate vectors or, alternatively, all on episomal type vector. Indeed, even under continuous selection pressure, many episomal type vectors suffer stability problems if they are large or are present at relatively low copy number. An object of the present invention is therefore to provide a method for expressing recombinant collagen and other triple helical proteins from yeast host cells wherein the introduced DNA sequences are stably retained and segregated independent of continuous selection pressure.

Summary of the Invention:

Thus, in a first aspect, the present invention provides a method of producing a hydroxylated triple helical protein in yeast comprising the steps of:

introducing to a suitable yeast host cell a first nucleotide sequence encoding P4H α subunit, a second nucleotide sequence encoding P4H β subunit and one or more product-encoding nucleotide sequences which encode(s) a polypeptide(s) or peptide(s) which, when hydroxylated, form the said hydroxylated triple helical protein, each of said first, second and product-encoding nucleotide sequences being operably linked to promoter sequences, and

culturing said yeast host cell under conditions suitable to achieve expression of said first, second and product-encoding nucleotide sequences to thereby produce said hydroxylated triple helical protein; wherein said method is characterised in that the step of introducing the first, second and product-encoding nucleotide sequences results in the said first, second and product-encoding nucleotide sequences, together with their respective operably linked promoter sequences, being borne on one or more replicable DNA molecules that are stably retained and segregated by said yeast host cell during said step of culturing.

In a second aspect, the present invention provides a yeast host cell capable of producing a hydroxylated triple helical protein, said yeast host cell including a first nucleotide sequence encoding P4H α subunit, a second nucleotide sequence encoding P4H β subunit and one or more product-encoding nucleotide sequences which encode(s) a polypeptide(s) or peptide(s) which, when hydroxylated, form the said hydroxylated triple helical protein, each of said first, second and product-encoding nucleotide sequences being operably linked to promoter sequences, and wherein said first, second and product-encoding nucleotide sequences, together with their respective operably linked promoter sequences, are borne on one or more replicable DNA molecules that are stably retained and segregated by said yeast host cell.

In a third aspect, the present invention provides a triple helical protein produced in accordance with the method of the first aspect.

In a fourth aspect, the present invention provides a biomaterial or therapeutic product comprising a triple helical protein produced in accordance with the method of the first aspect.

Detailed disclosure of the Invention:

The method according to the invention requires that the first and second nucleotide sequences encoding the P4H α and β subunits and the product-encoding nucleotide sequences be introduced to a suitable yeast host cell in a manner such that they are borne on one or more DNA molecules that are stably retained and segregated by the yeast host cell during culturing. In this way, all daughter cells will include the first, second and product-encoding nucleotide sequences and thus stable and efficient expression of a hydroxylated triple helical protein product can be ensured throughout the culturing step and without the use of continuous selection pressure.

The method according to the invention can be achieved by; (i) integrating (e.g. by homologous recombination) one or more of the exogenous nucleotide sequences (i.e. one or more of the first, second and product-encoding nucleotide sequences) into one or more chromosome(s) of the yeast host cell, or (ii) including one or more of the exogenous nucleotide sequences within one or more vector(s) including a centromere (CEN) sequence(s). Alternatively, a combination of these techniques may be used or one or both of these techniques may be used in combination with the use of one or two high copy number plasmid(s) which include the remainder of the exogenous nucleotide sequences. For example, the first and second nucleotide sequences encoding the P4H α and β subunits may be integrated into a host chromosome while the product-encoding sequences may be included on vector(s) including a CEN sequence or on a high copy number vector(s).

Preferably, the method of the invention is achieved by including the exogenous nucleotide sequences within a vector(s) including a CEN sequence. Particularly preferred are the CEN sequence-including YAC (yeast artificial chromosome) vectors (Cohen *et al.*, 1993) and pYEUra3 vectors (Clontech, Cat. No 6195-1). Other vectors including a CEN sequence may be generated by cloning a CEN sequence into any suitable expression vector.

Where one or more of the exogenous nucleotide sequences are included in a high copy number vector(s), it is preferred that the high copy number vector(s) is/are selected from those that may be present at 20 to 500 (preferably, 400 to 500) copies per host cell. Particularly preferred high copy number vectors are the YE_p vectors.

The method according to the invention enables the production of hydroxylated triple helical proteins. The term "triple helical protein" is to be

understood as referring to a homo or heterotrimeric protein consisting of a polypeptide(s) or peptide(s) which include at least a region having the general peptide formula: $(\text{Gly X Y})_n$, in which Gly is glycine, X and Y represent the same or different amino acids (the identities of which may vary from Gly X Y triplet to Gly X Y triplet) but wherein X and Y are frequently proline which in the case of Y becomes, after modification, hydroxyproline (Hyp), and n is in the range of 2 to 1500 (preferably 10 to 350), which region forms, together with the same or similar regions of two other polypeptides or peptides, a triple helical protein conformation. The term therefore encompasses natural and synthetic collagens, natural and synthetic collagen fragments, and natural and synthetic collagen-like proteins (e.g. macrophage scavenger receptor and lung-surfactant proteins) and as such includes any procollagen and collagen (e.g. Types I-XIX) with or without propeptides, globular domains and/or intervening non-collagenous sequences and, further, with or without native or variant amino acid sequences from human or other species. Synthetic collagen and fragments encompassed by the term "triple helical protein" may also include non-collagenous, non-triple helical domains at the amino and/or carboxy terminal ends or elsewhere.

Accordingly, product-encoding nucleotide sequence(s) suitable for use in the method according to the invention may be of great diversity. It is, however, preferred that the product-encoding nucleotide sequence(s) be selected from nucleotide sequences encoding natural collagens and fragments thereof, such as COL1A1 (D'Alessio *et al.*, 1988; Westerhausen *et al.*, 1991), COL1A2 (de Wet *et al.* 1987), COL2A1 (Cheah *et al.*, 1985) and COL3A1 (Ala-Kokko *et al.* 1989) and fragments and combinations of these, and synthetic collagens and fragments thereof.

Product-encoding nucleotide sequence(s) which encode natural or collagen fragments may encode fragments which include or exclude the N-pro-peptide region, the N-telopeptide, the C-telopeptide or the C-propeptide or various combinations of these.

Product-encoding nucleotide sequences which encode synthetic collagens and fragments thereof, preferably encode a polypeptide(s) or peptide(s) of the general formula: $(A)_l(B)_m(\text{Gly X Y})_n(C)_o(D)_p$, in which Gly is glycine, X and Y represent the same or different amino acids, the identities of which may vary from Gly X Y triplet to Gly X Y triplet but wherein Y must be \geq one proline, A and D are polypeptide or peptide domains which may or

may not include triple helical forming (Gly X Y)_n repeating sequences, B and C are intervening sequences which do not contain triple helical forming (Gly X Y)_n repeating sequences, n is in the range of 2 to 1500 (preferably, 10 to 300) and l, m, o and p are each independently selected from 0 and 1.

5 The product-encoding nucleotide sequence(s) may include a sequence(s) encoding a secretion signal so that the polypeptide(s) or peptide(s) expressed from the product-encoding nucleotide sequence(s) are secreted.

10 Expression of the product-encoding nucleotide sequence(s) may be driven by constitutive yeast promoter sequences (e.g. ADH1 (Hitzeman *et al*, 1981; Pihlajaniemi *et al*., 1987), HIS3 (Mahadevan & Struhl, 1990), 786 (no author given, 1996 Innovations 5, 15) and PGK1 (Tuite *et al*, 1982), but more preferably, by inducible yeast promoter sequences such as GAL1-10 (Goff *et al* 1984), GAL7 (St. John & Davis, 1981), ADH2 (Thukral *et al*, 1991) and
15 CUP1 (Macreadie *et al*, 1989).

20 The first and second nucleotide sequences encoding the P4H α and β subunits can be of any animal origin although they are preferably of avian or mammalian, particularly human, origin (Helaakoski *et al*., 1989). It is also envisaged that the first and second nucleotide sequences may originate from different species. In addition, the second nucleotide sequence encoding the P4H β subunit may include a sequence encoding an endoplasmic reticulum (ER) retention signal (e.g. HDEL, KDEL or KEEL) with or without other target signals so as to allow expression of the P4H in the ER, cytoplasm or a target organelle or, alternatively, so as to be secreted.

25 Expression of the first and second nucleotide sequences may be driven by constitutive or inducible yeast promoter sequences such as those mentioned above. It is believed, however, that it is advantageous to achieve expression of the α and β subunits in a co-ordinated manner using same or different promoter sequences with same induction characteristics, but
30 preferably by the use of a bidirectional promoter sequence. Accordingly, it is preferred that the first and second nucleotide sequences be expressed by the yeast GAL1-10 bidirectional promoter sequence, although other bidirectional promoter sequences would also be suitable.

35 Multiple copies of the first, second and/or product-encoding nucleotide sequences may be introduced to the yeast host cell (e.g. present on a YAC vector or integrated into a host chromosome). It may be

particularly advantageous to provide the product-encoding nucleotide sequence(s) in multicopy and, accordingly, it may be preferred to introduce the product-encoding nucleotide sequence(s) on a high copy number plasmid (e.g. a YE_p plasmid).

5 The introduced first, second and product-encoding nucleotide sequences may be borne on one or more stably retained and segregated DNA molecules. Where borne on more than one DNA molecule, the DNA molecules may be a combination of host chromosome(s) and/or CEN sequence-including vector(s) in combination with high copy number
10 vector(s). Some specific examples of yeast host cells suitable for use in the method according to the invention, are transformed with the following DNA molecules:

1. YE_p-P3 + pYE_{Ura3}- $\alpha\beta$,
2. YE_p-P3 + pYAC $\alpha\beta$
- 15 3. YE_pCEN-P3 + pYE_{Ura3}- $\alpha\beta$
4. YE_pCEN-P3 + pYAC $\alpha\beta$
5. pYAC-P3 + pYAC $\alpha\beta$
6. pYAC-P3 + pYE_{Ura3}- $\alpha\beta$
7. pYAC $\alpha\beta$ -P3;

20 wherein P3 represents a product-encoding nucleotide sequence(s), α and β represent, respectively, nucleotide sequences encoding the P4H α subunit and P4H β subunit, CEN represents an introduced centromere sequence. The pYE_{Ura3} and pYAC vectors include CEN sequences.

25 Triple helical protein products produced in accordance with the method of the invention may be purified from the yeast host cell culture by techniques including standard chromatographic and precipitation techniques (Miller & Rhodes, 1982). For collagens, pepsin treatment and NaCl precipitation at acid and neutral pH may be used (Trelstad, 1982). Immunoaffinity chromatography can be used for constructs that contain
30 appropriate recognition sequences, such as the Flag sequence which is recognised by an M1 or M2 monoclonal antibody, or a triple helical epitope, such as that recognised by the antibody 2G8/B1 (Glattauer *et al.*, 1997).

35 Yeast host cells suitable for use in the method according to the invention may be selected from genus including, but not limited to, *Saccharomyces*, *Kluveromyces*, *Schizosaccharomyces*, *Yarrowia* and *Pichia*.

Particularly preferred yeast host cells may be selected from *S. cerevisiae*, *K. lactis*, *S. pombe*, *Y. lipolytica* and *P. pastoris*.

As indicated above, it is particularly preferred that the first, second and product-encoding nucleotide sequences be introduced to the yeast host cell by transformation with one or more YAC vectors. YAC vectors are linear DNA vectors which include yeast CEN sequences, at least one autonomous replication signal (e.g. *ars*) usually derived from yeast, and telomere ends (again, usually derived from yeast). They also generally include a yeast selectable marker such as URA3, TRP1, LEU2, or HIS3, and in some cases, an ochre suppressor (e.g. *sup4-o*) which allows for red/white selection in adenine requiring strains (i.e. the mutation of the adenine gene being due to a premature ochre stop codon). More commonly, two yeast selectable markers are included, one on each arm of the artificial chromosome (each arm separated by the CEN). This allows selection of only those transformed hosts containing YACs with introduced sequences of interest within the desired restriction cloning site. That is, correct insertion of the sequences of interest (e.g. an expression cassette) rejoins the two arms of the restricted YAC, thus rendering transformants prototrophic for both markers. YACs have been designed to allow for the introduction of large exogenous nucleotide sequences (i.e. of the order of 100kb or more) into yeast host cells. The present inventors have hereinafter shown that such YACs may be used for the stable expression of multiple exogenous nucleotide sequences (e.g. nucleotide sequences encoding a natural collagen and both the α and β subunits of P4H).

In some embodiments of the invention, it may be preferred that one or more (but not all) of the first, second and product-encoding nucleotide sequences be introduced to the yeast host cell by transformation with one or two YEp vectors. YEp vectors carry all or part of the yeast 2μ plasmid with at least the *ori* of replication. They also include a yeast selectable marker such as HIS3, LEU2, TRP1, URA3, CUP1 or G418 resistance, and often also contain a separate *ori*, generally *ColE1*, and markers, such as ampicillin resistance, for manipulation in *E.coli*. They show high copy number, for example 20-400 per cell, and are generally efficiently segregated. Stability during cell division is dependent on the vector also containing the REP2/STB locus from the 2μ plasmid. However, stability is not as good as endogenous 2μ plasmid

of the host, particularly when heterologous genes are induced for expression. Stability also declines with increasing plasmid size. (Wiseman, 1991).

The terms "comprise", "comprises" and "comprising" as used throughout the specification are intended to refer to the inclusion of a stated component or feature or group of components or features with or without the inclusion of a further component or feature or group of components or features.

The invention will now be described by way of reference to the following non-limiting examples and accompanying figures.

Brief description of the accompanying figures:

Figure 1 shows, diagrammatically, the construction of the expression vector pYEUra3.2.12 β #39 α #5 (labeled pYEUra3-M β α).

Figure 2 shows the nucleotide sequence for the COLIII1.6 kb DNA.

Figure 3 shows, diagrammatically, regions of the human collagen III gene that have been isolated by PCR. The 1.6kb DNA used in the examples hereinafter is also shown. It is to be understood that the other regions shown in the figure could substitute for the COLIII1.6kb DNA in those examples.

Figure 4 shows, diagrammatically, the construction of the expression vector YEpFlagCOLIII1.6kb (labeled YEpFlag-C3).

Figure 5 shows, diagrammatically, the construction of pYAC5 β α .

Figure 6 shows, diagrammatically, the construction of pYAC β α -COL III1.6 kb.

Figure 7 outlines the construction of synthetic collagen products.

Figure 8 provides the nucleotide sequence for SYN-C3 together with the amino acid sequence of the encoded polypeptide.

Examples:

Example 1: Construction of a yeast vector for co-ordinated co-expression of the α and β subunits of Prolyl-4-hydroxylase.

Production of yeast expression vector:

pYEUra3 (Clontech) contains the bidirectional promoter for GAL1-10 expression. Induction by galactose in the absence of glucose results in high level expression from pGAL1 of any protein encoded by DNA sequences inserted in the correct orientation in the MCS (multiple cloning site) [either

XhoI, Sall, XbaI or BamHI sites] provided there is an initiating ATG start codon. For pGAL10, expression induced by galactose occurs if the DNA sequences to be expressed are inserted in frame with the ATG codon of GAL10 when said DNA sequences to be expressed is inserted in the EcoRI site.

In order to utilise the EcoRI site for cloning, without the necessity that the insert be in frame with the ATG of GAL10 for expression, it was necessary to modify pYEura3 to remove the GAL10 initiation codon. This was done as follows. A PCR fragment was generated using pYEura3 as template and primers 3465 [5'CTG.TAG.Agg.atc.cCCGGG.TAC.GGA.GC-3', where the nucleotides shown in lower case code for a BamHI site] and primer 1440 [5'TTA.TAT.Tga.att.cTC.AAA.AAT.TC-3' where the nucleotides shown in lower case specify an EcoRI restriction site]. Primer 1440 introduces an EcoRI site preceding the initiating ATG of GAL10 in pYEura3. The PCR fragment was restricted with BamHI and EcoRI and cloned into pYEura3 similarly digested with BamHI and EcoRI, replacing the BamHI-EcoRI fragment containing an ATG start codon with a BamHI-EcoRI fragment lacking this ATG, to generate plasmid pYEura3.2.12. The EcoRI site can then be used as a cloning site for which an initiating codon must be provided by the inserted DNA sequence as with the MCS at the other end of the promoter, thus placing it under control of the bidirectional pGAL1-10 promoter and rendering expression inducible by galactose as are DNA sequences inserted in the MCS at the other end of the promoter. Cloning DNA sequences in the MCS and in the EcoRI site allows for co-ordinate expression by the bidirectional promoter when induced by galactose.

Isolation of DNA molecules encoding the α and β subunits of P4H:

The α subunit of P4H was PCR amplified from cDNA (Clontech Human Kidney Quick Clone™ cDNA Cat. #7112-1) using primers 1826 [5'-TGT.AAA. ATT.AAA.gga.tcc.CAA.AG.ATG.TGG.TAT-3', lower case encodes BamHI site, ATG initiating codon for α subunit] and 1452 [5'-GCCG.gga.tcc.TG. TCA.TTC.CAA.TGA.CAA.CGT-3', lowers case encodes BamHI site, TCA translation stop codon]. Two isoforms were obtained and cloned into the BamHI site of pBluescript II SK+ [Stratagene Cat. # 212205] as storage vector to give pSK+ α .1 (form I) and pSK+ α .2 (form II) . There are no BamHI sites in the DNA encoding the α subunit. The signal sequence for secretion is present in the BamHI fragment of both forms.

The β subunit of P4H [also known as PDI/protein disulfide isomerase] [Pihlajaniemi *et al.*, 1987] was PCR amplified from cDNA (Clontech Human Kidney Quick Clone™ cDNA Cat.#7112-1) using primer pairs 2280 [5'-AC.TGG.ACG.GAT.CCC.GAG.CGC.CCC.GCC.TGC.
5 TCC.GTG.TCC.GAC.ATG-3'] and 2261 [5'-G.GTT.CTC.CTT.ggt.gac.cTC.CCC.TT-3', where the nucleotides shown in lower case encode a BstEII site] for the amino terminal part of the β subunit and primer pairs 2260 [5'-GAA.GGG.GAG.gtc.acc.AAG.GAG.AAC-3', where the lower case nucleotides encode a BstEII site] and 1932 [5'-CC.TTC.AGG.ATC.CTA.
10 TTA.GAC.TTC.ATC.TTT.CAAC.AGC-3'] for the carboxy terminal part of the β subunit. The two PCR fragments for the β subunit were then ligated together following BstEII digestion, to produce a single fragment encoding the entire β subunit. This fragment was then amplified using the primers 2280 [5'-AC.TGG.Acg.gat.ccC.GAG.CGC.CCC.GCC.TGC.TCC.
15 GTC.TCC.GAC.ATG-3', where ggatcc encodes a BamHI site, and ATG is the initiating codon of the β -subunit] and primer 1932 [5'-CC.TTC.Agg.atc.cTA.TTA.GAC.TTC.ATC.TTT.CAC.AGC-3', where ggatcc encodes a BamHI site and TTA is the translation stop codon for the β subunit] and then cloned into the BamHI site of pBluescript SKII+ to generate the storage vector pSK+ β . Subsequently, the BamHI fragment of pSK+ β was amplified by
20 using primers 2698 [5'-CTA.GTT.gaa.ttc.TAC.ACA.ATG.CTG.CGC.CGC.GCT.CTG.CTG-3', where gaattc encodes an EcoRI site and the ATG. is the initiating codon of the β subunit] and 2699 [5'-GCA.ATG.gaa.ttc.TTA.TTA.CAG.TTC.GTG.CAC.AGC.TTT-3', where gaattc encodes an EcoRI site, and
25 TTA. TTA. provides two translation stop codons, and GTG. changes a lysine [K] residue to a histidine [H] residue to provide a native yeast ER retention signal, HDEL (i.e. His.Asp.Glu.Leu) ather than a mammalian KDAEL ER retention signal]. The resultant PCR fragment was then blunt end cloned into the SrfI site of pCRScript [Stratagene, Cat.# 211190] to generate pCRScript β .
30 After retrieving the EcoRI fragment containing the β subunit from pCRScript β by EcoRI digestion, the fragment was again cloned into the EcoRI site of pCRScript to generate pCRScript β EcoRI#4.

Construction of yeast expression vector including fragment encoding the α and β subunit of P4H:

The β subunit fragment was obtained as an EcoRI fragment from EcoRI digestion of pCRScript β EcoRI#4. This EcoRI fragment was cloned into the EcoRI site of pYEura3.2.12 to generate plasmid pYEura3.2.12 β #39. The α subunit fragment from pSK+ α .1 was re-excised from pSK α .1 by BamHI and cloned into the BamHI site of pYEura3.2.12 β #39 to give pYEura3.2.12 β #39 α #5] (Figure 1). The β subunit fragment is under control of pGAL10 and the α subunit fragment is under control of pGAL1. This is a bidirectional promoter and allows co-ordinated induced expression of both subunits of prolyl-4-hydroxylase. Both fragments provide a native ATG initiating codon for translation. The encoded β subunit has its own signal secretion signal and a HDEL endoplasmic retention (ER) sequence at the carboxy terminus of the protein. While the encoded α subunit with its own signal sequence has no ER retention signal it should, nevertheless, be retained through its interaction with the β subunit.

Example 2: Co-ordinated co-expression of a collagen segment and prolyl-4-hydroxylase (α and β subunit) and synthesis of hydroxylated collagen Type III in yeast.

A 1.6 kbp recombinant collagen fragment was generated by PCR using primers 1989 [Forward primer 5'-gct.agc.aag.ctt GGA.GCT.CCA. GGC.CCA.CTT.GGG.ATT.GCT.GGG-3'] and 1903 [Reverse primer 5'-tcg.cga.tct.aga.TTA.TAA.AAA.GCA.AAC.AGG.GCC.AAC.GTC.CAC. ACC-3'] homologous to a region of the collagen type III alpha I chain (COL3A1). The template for isolation of the fragment of type III collagen alpha 1 chain was prepared from Wizard purified DNA obtained from a cDNA library [HL1123n Lambda Max 1 Clontech Lot#1245, Human Kidney cDNA 5'-Stretch Library].

The actual size of the isolated 1.6 kbp fragment is 1635 bp, comprising 1611 bp of COL3A1 DNA flanked either side by 12bp derived from the primers. The 1611 bp of COL3A1 DNA corresponds to nucleotides #2713-4826 (i.e codon #905-1442) of the full-length coding sequence, thereby spanning a portion of the α -helix region, all of the C-telo-peptide, all of the C-pro-peptide and stop codon.*¹ The nucleotide sequence for the COL3A1 DNA is provided at Figure 2. The region covered by the COL3A1

DNA is shown at Figure 3. The 1.6kbp fragment has a NheI [GCTAGC] site and a HindIII [AAGCTT] site added at the 5'-end and a XbaI [TCTAGA] site and a NruI [TCGCGA] site added at the 3' end [where the 5' end is taken to be the forward direction of the reading frame, ie the amino terminal end of the derived coding sequence, and the 3' end is that derived from the reverse primer corresponding to the 3' end of the gene and carboxy end of the derived amino acid sequence]. This confers portability on the collagen fragment.

The 1.6kbp fragment was cloned into the SmaI site of YEplFlag1 [IBI Catalogue #13400] so that the coding sequence is fused in frame with the vector expressed Flag protein. This allows for in frame expression of the introduced collagen gene fragment as a fusion protein when grown on ethanol. The blunt end cloning was performed by ligation of the SmaI digested vector sequence [gel purified] and the 1.6kbp PCR fragment [gel purified, non-phosphorylated] at 20°C, in the presence of SmaI, to prevent recircularisation of the vector alone and reduce the level of false positive transformants obtained. There are no SmaI, NheI, HindIII, XbaI or NruI sites in the fragment of collagen DNA used in the cloning.

Small scale mini-preparations [prepared using Bio101 columns and described methods for their use] of DNA from ampicillin resistant transformant colonies of *E.coli* were screened by restriction enzyme analysis. 10ml cultures rather than 1 ml cultures were required to prepare an adequate level of DNA for analysis, as YEplFlag plasmids do not appear to be at a high copy number in *E.coli*.

The fusion protein was of the form : yeast α factor signal sequence for direction to the ER and commitment to the yeast secretion pathway, yeast α factor propeptide with cleavage sites for kex 2-endopeptidase, resulting in removal of all α -factor amino acid residues and generation of a free Flag-tagged amino terminal end, Flag peptide for detection and tagging of the fusion protein (8 amino acid residues), linker peptide (4 amino acid residues), collagen helix (255 amino acid residues), collagen C-telopeptide [C-tel] (25 amino acid residues) and C-propeptide [C-pro] (255 amino acid residues) (for aid in formation of triple helix). The expected Flag-tagged protein consists of 547 amino acid residues with a expected MW of ~60kDa].

Expression of the fusion protein in YEplFlag1 is under the control of the ADH2 promoter which is repressed by glucose but active in the presence

of ethanol [a by-product of glucose metabolism]. There are multiple copies of the vector in individual yeast transformants due to the presence of the yeast 2 micron origin of replication in the vector, which leads to elevated expression of the 1.6 kbp PCR collagen fragment when glucose repression is lifted by consumption of glucose during growth. One unique feature of this cloning scheme is that inserts of the 1.6kbp collagen fragment in the wrong orientation will not form fusion products as the terminal leucine residue preceding the stop codon is coded by the codon AAT. In reverse orientation this generates a stop codon TAA. The result of incorrect insertion is the addition of only a single leucine coding codon [the stop codon TAA in reverse is AAT] following the Flag sequence before the protein is terminated.

The amino acid sequence of the Flag-tagged fusion protein at the point of fusion is N-Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys-[Flag]-Ala-Ser-Lys-Leu-[linker]-Gly-Ala-Pro-Gly-Pro-Leu-Gly-Ile-Ala-[α -helix].

The YEpFlag collagen construct [hereinafter referred to as YEpFlag COLIII1.6kb; Figure 4] was introduced into a tryptophan prototrophic yeast strain such as for example BJ3505 [a pep4::HIS3 prb-1.6R HIS3 lys2-208 trp1-101 ura3-52 gal2 can1], BJ5462 [α ura3-52 trp1 leu2-1 his3-200 pep4::HIS3 prb-1.6R can1 GAL], (YGSG) JHRY1-5D α [α his4-519 ura3-52 leu2-3 leu2-112 trp1 pep4-3] or KRYD1[BJ3505xBJ5462 diploid] by transformation using electroporation, lithium acetate or spheroplast regeneration. Tryptophan auxotroph transformants were obtained, grown to high cell density in selective media [lacking tryptophan] followed by transfer to YPHSM, YEPM or YEPD or YEPGal, YEPE as described in the protocol provided with the YEpFlag expression system [IBI catalogue #13400]. At 3-9 days following inoculation 1ml aliquot's of culture were made and pellets and supernatants separated by centrifugation at 13000rpm in a benchtop centrifuge. Total yeast pellets were resuspended in 100 μ l of gel loading buffer [5xSDS] containing PMSF [0.002M], vortexed vigorously for 2 minutes, and boiled for 5 minutes. From the pellets 900 μ l supernatants were retained to which 100 μ l 5xSDS/0.002M PMSF was added, and treated as described for the pellets. For both pellets and supernatants 20 μ l aliquot's were assayed by Western blot analysis of SDS-PAGE yeast total protein or of supernatants [media] following transfer to nitrocellulose and prehybridisation of the filters in blotto. Western blotting was carried out using α -Flag MAb M1 [against N-terminal free Flag] (International Biotechnologies Inc., (Eastman Kodak) Cat. No. IB13001) or M2

[against Flag] (International Biotechnologies Inc., (Eastman Kodak) Cat. No. IB13010).

Western blots revealed the presence of a protein band of approximately 60kDa. This is the expected size of a protein fusion containing Flag-helix-C-tel-C-pro. After prolonged incubation the Flag responsive antibodies detected the appearance of the fusion product in the media. Detection in both pellet and media supernatant with M1 antibody demonstrates that the α factor leader has been completely removed. No precursor forms with α factor pro-region [glycosylated or not] were observed.

No band corresponding to 60kDa was obtained which hybridised to M1 or M2 with proteins obtained from untransformed yeast hosts. When yeast transformed with YEpFlag [no insert] alone was used, bands were obtained in pellets, but only with M2 MAb. These bands correspond to un-secreted α -proregion-with C-terminal Flag and various glycosylated forms of the same. No Flag is detected in supernatants but this is to be expected as it is only 8 amino acids long. No expression from the ADH2 promoter for any construct is observed in the presence of glucose.

YEpFlagCOLIII 1.6kb was also co-introduced [co-transformed] into yeast strains such as BJ5462 and KR DY1 which are capable of growth on galactose along with pYEUra3 [Clontech] [pYEUra3 and its derivatives contain the bidirectional GAL1-10 promoter. Both the ADH2 and GAL1-10 promoters are repressed by glucose. The GAL1-10 promoter is induced by galactose] or pYEUra3.2.12 [a modification of the Clontech parent vector which allows cloning of genes into an EcoRI site without the necessity of the introduced gene being in the correct reading frame] or pYEUra3.2.12 β #39 [in which the DNA encoding the β subunit (equivalent to protein disulfide isomerase of prolyl-4-hydroxylase is cloned into the EcoRI site of pYEUra3.2.12 under control of GAL10 promoter] or pYEUra3.2.12 β #39 α #5 [in which the DNA encoding the α subunit of P4H is cloned into the BamHI site of pYEUra3.2.12 β #39 under control of the GAL1 promoter].

Transformants were selected on media lacking tryptophan or uracil or lacking both tryptophan and uracil. As previously done with tryptophan transformants obtained above with YEpFlag or YEpFlagCOLIII1.6kb, transformants were grown in selective media prior to growth in YPHSM, YEPM, YEPD, YEPG or YEPE and after 4 days galactose was added to a final concentration of 2%, 0.5% or 0.2%. Total yeast protein or supernatants were

analysed by Western blot analysis as described above except that a third MAb [5B5 against the β subunit] (Dako Corporation, Cat. No. M877) was also used.

Western blot analysis revealed the presence of a ~ 60 kDa band in trp^- or $\text{trp}^- \text{ura}^-$ yeast transformed with YEpFlag COLIII1.6kb but not YEpFlag alone when screened with MAb M1 or M2 as was previously the case with transformants obtained with single plasmid transformation.

Analysis also showed the presence of a ~ 60 kDa band in ura^- or $\text{ura}^- \text{trp}^-$ but not trp^- yeast transformants transformed with pYEUra3.2.12 β #39 or pYEUra3.2.12 β #39 α #5 or cotransformed with same plus YEpFlag or YEpFlagCOLIII 1.6kb when screened with anti- β subunit MAb 5B5 but only following induction with galactose and only when galactose was between 0.2 and 0.5% and not at 2%. The expected size for the β subunit is also 60kDa. This band is not detected by M1 or M2 in uracil auxotrophic yeast transformed with pYEUra3.2.12 β #39 or pYEUra3.2.12 β #39 α #5 alone.

At the time of the experimentation, an antibody for the detection of expression of the α subunit from the bidirectional GAL1,10 promoter in pYEUra3.2.12 β #39 α #5 was not available but as the promoters for both GAL1 and GAL10 are normally co-induced and under the control of the same UAS (upstream activation sequence) in yeast it was assumed that the α subunit is also transcribed and expressed where the β subunit is demonstrated to be expressed. To test this, the capacity for pYEUra3.2.12 β #39 α #5 / YEpFlag COLIII 1.6kb co-transformants induced with 0.2% galactose following at least 4 days growth on YPHSM to produce functional P4H was examined. Galactose was added following the clear demonstration of the expression of Flag-collagen by a positive response of yeast protein to M1 or M2 in Western blots and the absence of a response to MAb 5B5 against β subunit. Following induction with galactose [16hrs] protein was again examined and the presence of M1 or M2 responsive bands and 5B5 responsive bands were separately demonstrated. Protein was transferred to PVDF membrane following SDS-PAGE and the membrane sliced into strips. Membrane strips containing protein from the region corresponding to the 60kDa responsive area was subject to hydrolysis and amino acid analysis. Amino acid analysis revealed the presence of hydroxyproline in this material from co-transformants of yeast co-transformed with YEpFlagCOLIII1.6kb and pYEUra3.2.12 β #39 α #5 after induction with 0.2% galactose but no

hydroxyproline was detected with protein from control samples with or without galactose.

The media used contains peptone derived from bovine protein hydrolysates but no hydroxyproline was found in total yeast grown on this media nor in any of the singly transformed yeast [one vector alone]. Only in yeast co-transformants was hydroxyproline detected in the 60kDa bands and then only when galactose was added. Uninduced co-transformants [no galactose] in which Flag detected collagen was expressed did not contain any hydroxyproline in the 60kDa band excised from PVDF following transfer.

Hydroxyproline was only found in the 60kDa region and not in other regions of the blot.

The clear evidence then, is that following galactose induction of pEUra3.2.12 β #39 α #5 a product is produced in yeast which is capable of hydroxylating the proline residues of a co-expressed Flag-tagged collagen fragment. Such activity is not found in yeast untransformed or transformed with pYEura3.2.12 β #39 [no α subunit] or in uninduced yeast grown on ethanol or glucose.

A clear advantage of this method of co-expression for the production of hydroxylated collagen in yeast is the co-ordinated expression of the three genes that is possible in co-transformants. Another advantage is that the α and β subunits themselves are co-ordinately expressed. A third advantage is that the $\alpha\beta$ expression vector (i.e. pEUra3.2.12 β #39a#5) contains a centromere sequence and behaves as a mini-chromosome. It is therefore very stable and does not require selection pressure to be maintained for its stability. The removal of selection pressure in yeast does not appear to effect the stability of the YEpFlag collagen construct as it is in very high copy number, but clearly the ability to only be concerned with maintenance of a single plasmid in the absence of selection pressure is important rather than balancing the effects of selection pressure on the stability of three separate plasmids if the α , β and collagen fragments were separately cloned on multicopy vectors. Also the use of a bidirectional promoter to express the α and β subunits simultaneously is of benefit rather than expressing them from different promoters on different plasmids in different amounts. The α subunit probably requires the synthesis of equal or higher levels of the β subunit for its correct assembly into functional P4H ($\alpha_2\beta_2$) enzyme and co-ordinated expression appears to be an efficient mechanism to ensure this.

5 *¹ [Codon numbering for collagen type III alpha 1 chain: ATC, codon #1; codon #1-codon #24, signal sequence; codon #25-codon #116, N-pro-peptide sequence, codon #117-codon #130, N-telo-peptide sequence; codon #131-codon #1161, α -helix sequence; codon #1162-codon #1186, C-telo-peptide; codon #1187-codon #1441, C-pro-peptide; codon #1442, stop] and [corresponding nucleotide numbering for collagen type III alpha 1 chain: nucleotide #1-72, signal sequence; nucleotide #73-348, N-pro-peptide sequence; nucleotide #349-390, N-telo-peptide; nucleotide #391-nt#3983, α -helix region; nucleotide #3984-4058, C-telo-peptide; nucleotide #4059-4823, C-pro-peptide sequence; nucleotide #4824-4826, stop codon].

10 **Example 3: Use of Yeast Artificial Chromosomes [YACs] for co-ordinated expression of the α and β subunits of Prolyl-4-hydroxylase [P4H].**

pYAC5 [11454bp] (Kuhn and Ludwig, 1994) was digested with BamHI to liberate the HIS3 gene [1210bp] from between the 2 telomere ends and with SalI-NruI to produce two fragments [left arm: fragment 1, 5448bp & right
15 arm: fragment2, 4238bp] which were gel purified. Fragment 1 was BamHI-telomere end-*E.coli* ori- β -lactamase gene [ampicillin-resistance] -TRP1-ARS1-CEN4-tRNAsup-o-SalI. Fragment 2 was BamHI-telomere end-URA3-NruI.

pYEura3.2.12 β #39 α #5 was digested with SalI-EcoRV to produce a P4H expression cassette fragment of the form SalI-XbaI-BamHI- α -ATG-
20 BamHI-pGAL1-10-EcoRI-ATG- β -EcoRI-SmaI-EcoRV [4864bp] which was gel purified. The expression cassette fragment encoding the α and β subunits of P4H under the control of a galactose inducible bidirectional promoter was ligated with fragments 1 and 2 of the BamHI-SalI-NruI digested pYAC5 and the ligation mix used to transform the following yeast strains: BJ2407 [α / α
25 prb1-11222/prb1-1122 prc1-407/prc1-407 pep4-3/pep4-3 leu2/leu2 trp1/trp1 ura3-52/ura3-52], KRYD1 [α / α ura3-52/ura3-52 trp1- Δ 101/trp1 lys2-208/LYS2 HIS3/his3 Δ 200 gal2/GAL2 can1/can1 pep4::HIS3/pep4::HIS3 prb1 Δ 1.6R/prb1.6R], GY1 [α leu2 ade1 trp1 ura3], JHRY1-5D α [α his4-519 ura3-52 leu2-3 leu2-112 trp1 pep4-3], and YPH150[α / α ura3-52/ura3-52 lys2-
30 801a/lys2-801a ade1-101o/ade1-101o leu2 Δ 1/leu2 Δ 1 trp1- Δ 63/trp1- Δ 63 his3 Δ 200/his3 Δ 200] using the method for lithium acetate transformation. Yeast strains were also transformed with pYAC5 digested with BamHI and undigested pYAC5.

Ura⁺ Trp⁺ co-transformants were obtained for all strains where the
35 two fragments of pYAC5 each carrying either TRP1 [SalI-CEN4-TRP1-BamHI] [fragment 1] or URA3 [NruI-URA3-BamHI] [fragment 2] as the selectable marker for transformation each on one arm of the YAC, had been linked together by the insertion of the P4H expression cassette into the SalI-EcoRV sites. This vector was designated pYAC5 $\beta\alpha$ (Figure 5). The vector was of the

form BamHI-telomere-URA3-NruI/EcoRV [both sites destroyed]- β -ATG-pGAL10-1-ATG- α -SalI-tRNA^{sup}-CEN4-ARS1-TRP1-AMPr-ori-telomere-BamHI. The presence of the CEN4 sequence means the vector behaves as a stable chromosome during replication and is segregated at least 1 copy per cell at mitosis and meiosis [as was the case for pYEura3.2.12 β #39 α #5]. The telomere ends mean that the vector is linear and stable.

Transformants and controls [pYAC5 alone (circular), pYAC5 linearised by BamHI digestion] were replica plated onto nitrocellulose filters laid over selective media [SD Complete lacking uracil and tryptophan] or rich media [YEpd] and incubated 2-5 days at 30C till confluent. Filters were transferred to selective media containing galactose [2%] instead of glucose or rich media containing galactose [2%] as well as glucose media plates and grown at 30C for periods between 2h-72h. At the end of incubation colonies were lysed on 0.1%SDS-0.2N NaOH-0.1% β -mercaptoethanol, washed with water and filters blocked with Blotto. Production of the α and β subunits of P4H was ascertained by hybridising the treated filters with MABs specific for the α [MAB 9-47H10] (ICN Biomedical Inc. Cat. No. 631633) and β [MAB 5B5] subunits. Colonies transformed with pYAC5 $\beta\alpha$ and induced with galactose showed hybridisation with MABs against the subunits of P4H demonstrating co-ordinated production of α and β from the bi-directional GAL 1-10 promoter. Controls filters and control yeast did not produce a response to P4H MABs. Yeast transformants carrying pYAC5 $\beta\alpha$ grown on glucose [a repressor of the bi-directional GAL 1-10 promoter] also did not produce a positive response.

Positive transformants identified in the above screening procedure were precultured/grown in 10ml liquid culture media containing selective media lacking ura and trp or rich media [containing glucose, glycerol or raffinose]. Aliquots were transferred to inducing media [selective or rich] containing 0.2-2% galactose. Where glucose was the carbon source pellets were washed in sterile water prior to induction. After 2-20h further growth at 30C cell pellets were collected, suspended in loading buffer and total yeast protein separated on SDS-PAGE and western blotted. Filters were blocked with blotto and hybridised with MABs against both of the P4H subunits. Only those yeast transformants carrying pYAC5 $\beta\alpha$ and induced with galactose gave the expected 60kDa bands for α and β subunits. This demonstrates that the P4H expression cassette has been functionally inserted

into pYAC5. The advantage of having the P4H cassette in the pYAC is twofold; [1] as with the case of pYEUra3.2.12 β #39 α #5 the presence of the CEN sequence means that the vector is stably maintained in this system when selection pressure is removed for growth in rich media, which
5 increases yield through increased cell density, and [2] the pYAC5 $\beta\alpha$ construct allows for the subsequent insertion of multiple and different triple helical protein expression cassettes.

Example 4: Co-expression of collagen/triple helical protein fragment(s) expressed on a multicopy plasmid and P4H subunits in yeast transformants carrying pYAC5 $\beta\alpha$.

Yeast host strains containing pYAC5 $\beta\alpha$ or pYAC5 were transformed with YEpFlagColIII 1.6kb or YEpFlag alone. The form of the collagen bearing vector was circular and multicopy. In this instance, as the YEpFlagColIII
15 1.6kb and the pYAC constructs both contain the same selectable marker, yeast transformants producing Flag tagged-collagen were identified by colony hybridisation with MAbs against Flag [M1 or M2]. Colonies were also screened for whether they carried extra copies of *bla* gene [multicopy] by identifying those colonies producing increased levels of β -lactamase by
20 PADAC assay (Macreadie *et al.*, 1994). In other examples, the multicopy plasmid could utilise a different selectable marker other than URA3 or TRP1 found on each arm of the YAC. Various co-transformant types carrying pYAC5 $\beta\alpha$ and YEpFlag ColIII 1.6kb were assayed as in Example 1 for collagen production, P4H subunit production, and P4H activity. Those co-
25 transformants containing pYAC5 $\beta\alpha$ plus YEpFlag ColIII 1.6kb were then screened as described in the previous example for hydroxylated collagen to identify 60kDa bands in western blots responding to MAbs against the α and β and Flag following induction. The α and β subunits were only identified following galactose induction. Hydroxylated protein was only identified
30 following induction of both the α and β subunits of P4H.

Example 5: Introduction of collagen expression cassette into pYAC5 and pYAC5 $\beta\alpha$.

YEplFlag was linearised by digestion with ScaI which cuts at a single recognition site in the ampicillin resistance gene for β -lactamase [*bla*]. There are no ScaI sites in the 1.6kb collagen fragment insert so ScaI could also be used to linearise YEplFlagCOLIII 1.6kb. Linear DNA was used to transform yeast containing pYAC5 or pYAC5 $\beta\alpha$. Yeast transformants producing Flag tagged-collagen were identified by colony hybridisation with MAb against Flag [M1 or M2]. Colonies carrying extra copies of *bla* gene [multicopy] were also identified. Those colonies producing increased levels of β -lactamase by the PEDAC assay were found to have inserted a copy of YEplFlag COLIII 1.6kb into the pYAC5 or pYAC5 $\beta\alpha$ vector of the host strain and correspond to those colonies positive to MAb M1 or M2. The increased β -lactamase activity is a result of gene amplification resulting from homologous recombination between the linearised *bla* gene on YEplFlagCOLIII 1.6kb and the *bla* gene on pYAC. The new plasmids formed by insertion into pYAC5 or pYAC5 $\beta\alpha$ of the YEplFlag COLIII 1.6kb vector were designated pYAC-COLIII 1.6kb and pYAC $\alpha\beta$ -COLIII 1.6kb (Figure 6). Expression experiments were performed and only those strains carrying all 3 genes on the YAC [pYAC $\beta\alpha$ -COLIII 1.6kb] and induced for P4H with galactose produced hydroxylated collagen.

Example 6: Cloning and expression of a synthetic collagen protein.

A strategy is described for the generation of "synthetic/novel" collagen proteins involving the *in vitro* assembly of synthetic oligonucleotides repeat sequences encoding the peptide GPP.GPP.GXY (where XY = LA, ER, PA or AP). The synthetic collagen sequences are engineered to contain a high percentage of proline residues as this residue has been shown to confer thermal stability to collagen molecules. The residue pairs chosen for the XY position (i.e. LA, ER, PA or AP), are selected since they appear in statistically higher amounts in fibrillar collagens.

Mixtures of synthetic oligonucleotides encoding GPP.GPP.GXY may be joined together to generate DNA fragments of discrete lengths, encoding synthetic collagen proteins of discrete molecular size and with different physical characteristics. These synthetic gene segments can be cloned into various expression vectors for subsequent production of a collagen product in yeast. An outline of the strategy for construction of a synthetic

oligonucleotide encoding a collagen is shown in Figure 7 where XY is shown, for the purposes of exemplification only, as ER, LA, AP, PA.

Such synthetic oligonucleotides have been synthesised and several libraries containing gene segments of various lengths have been generated by
 5 ligating these oligonucleotides together (maximum visible DNA length approx. 1000 base pairs coding for a polypeptide of ~ 350 amino acid residues).

Example 7: Construction of a synthetic hydroxylated triple helical protein for stable expression in yeast.

A region of Type III collagen was selected for its known capacity to bind and activate platelets [through an integrin binding site near -Gly-Leu-Ala-Gly-Ala-Pro-Gly-Leu-Arg]. A region of 5 GLY-X-Y repeats to the N-terminal side and 7 GLY-X-Y repeats to the C-terminal side were also
 15 included to form the basic repeat unit for inclusion in the synthetic fragment. The sequence of the repeat was GGKGDAGAPGERGPP-GLAGAPGLR-GGAGPPGPEGGKGAAGPPGPP. This corresponds to residues 637-681 (nucleotides 1909-2043) in the COL3A1 gene [with Met = 1]. At the 5'-end of the DNA an EcoRI site and NheI site was included such that the NheI site
 20 provided an initiating methionine. Thus the sequence at the amino end is MGAPGAP, where GAPGAP is the natural sequence flanking the repeat in COL3A1. The repeat was linked to a second repeat by a linker which introduced a Bsp120I site for later manipulations and provided the sequence GGP between the first and second repeat unit. The second repeat was linked
 25 to a third repeat by a linker which introduced a BssHII site [again for later manipulation] and resulted in the amino acid sequence GAR. The third repeat was flanked by 2 additional GPP triplets, a GCC triplet and finally GLEGPRG. This was a result of including coding sequence that provided for XhoI, SacII and NheI sites. These were included for flexibility of cloning at
 30 later stages. The NheI site provides an in frame stop codon.

The synthetic fragment was produced by PCR from primers against COL3A1 in 3 pieces initially. Fragment 1 was EcoRI-NheI-Met-[GAP]2-[REPEAT]1-Bsp120I. The primers for this were 5'-aattccatg-ggtgctccaggtgctcc-3' [up] [primer U101] and 5'-ggcc-acctggtggacctggtgg-3'
 35 [down] [primer D101]. The second PCR fragment used primers 5'-ggccc-ggtgtaagggtgacgc-3' [up] [primer U102] and 5'-cgcgacacctggtggacctgg-3'

[down] [primer D102]. For the 3rd repeat primer pairs used were 5'-cgcg-
 ggtggaagggtgacgctgg-3' [up] [primer U103] and 5'-acaaccctggtggacctggtggacc-
 tgggtggacctgggtgg-3' [down] [primer D103]. The three fragments form the PCR
 reactions were gel purified and ligated together. The DNA from the ligation
 5 mixture was then used as the template for a further round of PCR using
 primer U101 and a new primer at the 3' end [5'-ctagccccgcggaccctcgagaccaca-
 acaaccctggtgg-3'] [down] [primer D104]. A band of approximately 500 bp
 was produced and gel purified, digested with EcoRI-NheI and ligated to
 pYX141 (Ingenious Cat. No MBV-025-10) [LEU2-CEN-p786] also digested with
 10 EcoRI-NheI before being transformed into *E.coli*. Transformants were
 screened by PCR using primers for the second fragment and DNA from
 positive colonies were minipreped and screened by enzyme digestion with
 EcoRI-NheI for the presence of an insert of approximate 500 bp. This storage
 vector was designated pYX-SYN-C3-1. The EcoRI-NheI fragment was
 15 transferred to pYX243 [2u-LEU2-pGAL] (Ingenious Cat. No MBV-035-10) to
 give pYX-SYN-C3-2 and this plasmid was introduced into a yeast host cell
 including nucleotide sequence for the carrying the P4H α and β subunits
 [either pYEura3.2.12 β #39 α #5 or pYAC $\alpha\beta$]. Expression following galactose
 induction was determined by using a MAbs 2G8/B1 (Werkmeister & Ramshaw,
 20 1991) which recognises the sequence GLAGAPGLR. An EcoRI-SacII fragment
 from pYX-SYN-C3-2 was also introduced into the EcoRI-SacII of YEplFlag to
 produce YEplFlag-SYN-C3 and this too was introduced into a yeast host cell
 expressing P4H on induction by galactose. A product of approximately 18
 kDa [the expected size of SYN-C3] was detected in yeast induced with
 25 galactose by Western blotting.

The nucleotide sequence for SYN-C3 is provided at Figure 8 together
 with the amino acid sequence of the encoded product.

Example 8: The use of yeast other than *Saccharomyces cerevisiae*.

30 The GAL1-10 promoter is functional in *Kluyveromyces* whilst the
 ADH2 promoter is constitutively expressed in *S. pombe*. By shifting the
 expression cassettes to appropriate vectors, other yeast hosts can be used.
K. lactis for instance has been shown in some instances to display less
 proteolytic activity for recombinant products. Alternatively, *P. pastoris* could
 35 be used for multiple integration of the expression cassette for $\alpha\beta$ into the
 chromosome.

For expression in *P. pastoris*, the nucleotide sequence described in the previous example encoding the synthetic triple helical protein [SYN-C3] was inserted into the *P. pastoris* vector pPIC9 (Invitrogen, Cat. No. K1710-01) at the EcoRI-NotI sites [pPIC-SYN-C3]. Following digestion with either BglII or Sall, the plasmid was introduced into *P. pastoris* where it was integrated at either the AOX1 or HIS4 sites for BglII or Sall respectively. The nucleotide sequences encoding the P4H α and β subunits were also introduced into *P. pastoris* using the EcoRI site of pHIL-D2 (Invitrogen, Cat. No. K1710-01) for the β subunit and integration at HIS4 and the BamHI site of pHIL-S1 (Invitrogen, Cat. No. K1710-01) for the α subunit and subsequent integration HIS4. All three expression cassettes were under the control of the AOX1 promoter and induced by methanol.

Example 9: Enhanced expression of proly-4-hydroxylase α and β subunits from the GAL1-10 promoter by use of yeast with different backgrounds for control of galactose induced expression.

The plasmid pYEUra3.2.12 β #39 α #5 [encoding the α and β subunits of P4H under the control of the GAL1-10 bidirectional promoter] can be introduced into a yeast host cell with the following genotype : a or α , ura3 trp1 egd1 btt1. In these cells, the absence of the products for the EGD1 and BTT1 genes results in higher levels of galactose induced expression from GAL4 dependent promoters such as GAL2, GAL4, GAL7, GAL1-10, MEL1 (Hu & Ronne, 1994).

Another mechanism for enhanced expression is the use of a yeast host cell carrying multiple copies of the GAL4 (Johnston & Hopper, 1982) positive transcriptional activator under its own controlled induction by galactose. This leads to enhanced expression as there is no limit to the availability of the transcriptional activator for the GAL1-10 promoter. Similarly, the yeast host cell could contain multiple copies of the SGE1 gene (Amakasu *et al.*, 1993) which also leads to enhanced transcription from galactose induced promoters.

Various combinations of these backgrounds could also be utilised; that is egd1 btt1 SGE1^{mc} or egd1 btt1 GAL4^{mc} or egd1 btt1 SGE1^{mc} GAL4^{mc} [where mc represents multiple copies].

Example 10: Expression of collagen from promoters other than ADH2.

The collagen encoding nucleotide sequence in YEpFlag COL 1.6kb can be excised as a NheI or HindIII- XbaI or NruI fragment for insertion into other fusion vectors under the control of other promoters. Alternatively, the
5 pADH2- α signal-A-proregion-Flag collagen cassette can be excised as a NaeI or SacI - BglII or XbaI or SpeI or SnaBI or NotI, for example, and introduced into an appropriate vector such as YEplac181 (Gietz & Sugino, 1988) or pMH158 (Heuterspreute *et al.*, 1985) for expression in different copy numbers and host backgrounds or into vectors with CEN sequences. Alternatively,
10 CEN sequences can be introduced into the YEpFlag vector itself. The cassette can also be removed without the ADH2 promoter using NruI and introduced into an appropriate vector behind an appropriate promoter.

Collagen encoding nucleotide sequences can be expressed using the
15 CUP1 promoter in vectors such as pYELC5 (Macreadie *et al.*, 1989) as an alternative to the ADH2 promoter. This promoter is induced by addition of copper (i.e. copper sulfate) and may have the advantage of an increased reducing environment and enhancement of P4H activity during co-expression. A second promoter that can be used is the TIP1 promoter which is induced by cold shock. Here the stability of the expressed collagen may be
20 enhanced without the need for hydroxylation by inducing expression by shifting growing yeast from 30°C to 18°C.

The method according to the invention provides for the stable expression of triple helical proteins from yeast host cells. The products of the method may be natural and synthetic collagens, natural and synthetic
25 collagen fragments and natural and synthetic collagen-like proteins. Synthetic products may show enhanced or novel functions (e.g. inclusion of RGD and/or YIGSR sequences from fibronectin and laminin). The products may be used in a wide range of applications including bioimplant production, soft and hard tissue augmentation, wound/burn dressings,
30 sphincter augmentation for urinary incontinence and gastric reflux, periodontal disease, vascular grafts, drug delivery systems, cell delivery systems for natural factors and as conduits in nerve regeneration.

References:

- Ala-Kokko, L. *et al.* (1989) *Biochem J.* 260, 509-516
- 5 Amakasu, H. *et al.* (1993) *Genetics* 134, 675-683
- D'Alessio, M. *et al.* (1988) *Gene* 67, 105-115
- de Wet, W. *et al.* (1987) *J. Biol. Chem.* 262, 16032-16036.
- 10 Cheah, K.S.E. *et al.* (1985) *Proc. Natl. Acad. Sci. USA* 82, 2555-2559
- Cohen D *et al.*, (1993) *Nature* 366, 698-701.
- 15 Gietz, R.D. & Sugino, A. (1988) *Gene* 74, 527-534
- Glattauer, V. *et al.* (1997) *Biochem. J.* 323, 45-49.
- Goff, G. *et al* (1984) *Gene* 25, 179-188
- 20 Helaakoski, T. *et al.* (1989) *Proc. Natl. Acad. Sci. USA* 86, 4392-4396
- Heuterspreute, M. *et al.* (1985) *Gene* 34, 363-366
- 25 Hitzeman, R.A. *et al* (1981) *Nature* 293, 717-722
- Hu, G.Z. & Ronne, H. (1994) *Nucleic Acid Res.* 22, 2740-2743.
- Johnston, S.A. & Hopper, J.E. (1982) *Proc. Natl. Acad. Sci. USA* 79, 6971-6975.
- 30 Kuhn RM & Ludwig RA, (1994) *Gene* 141, 125-127.
- Larin Z *et al.*, (1996) *Nucleic Acid Research* 24 No. 21, 4192-4196.
- 35 Macreadie, I.G. *et al* (1989) *Plasmid* 21, 147-150

- Macreadie, I.G. *et al.* (1994) *Biotechnol. Applied Biochem.* 19, 265-269
- Mahadevan, S. & Struhl, K. (1990) *Mol. Cell Biol.* 10, 4447-4455, 786
- 5 Miller, E.J. & Rhodes, R.K. (1982) *Meth. Enzymol.* 82, 33-64.
- Pihlajaniemi, T. *et al.*, (1987) *EMBO J* 6, 643-649.
- 10 St. John, T.P. & Davis R.W. (1981) *J. Mol. Biol.* 152, 285-316
- Thukral, S.K. *et al* (1991) *Mol. Cell Biol.* 11, 699-704
- Trelstad, R.L. (1982) Native collagen fractionation. In, *Immunochemistry of*
15 *the Extracellular Matrix Vol. 1* (H. Furthmayr, ed.) CRC Press, 31-41.
- Tuite, M.F. *et al* (1982) *EMBO J.* 1, 603-608.
- Westerhausen, A *et al.* (1991) *Matrix* 11, 375-379
- 20 Werkmeister, J.A. & Ramshaw, J.A.M. (1991) *Biochem. J.*, 274, 895-898.
- Wiseman, A. (1991) *Genetically engineered proteins and enzymes from yeast: production control.* Ellis Horwood, New York.
- 25

It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the
30 invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

Claims:

1. A method of producing a hydroxylated triple helical protein in yeast comprising the steps of:

5 introducing to a suitable yeast host cell a first nucleotide sequence encoding P4H α subunit, a second nucleotide sequence encoding P4H β subunit and one or more product-encoding nucleotide sequences which encode(s) a polypeptide(s) or peptide(s) which, when hydroxylated, form the said hydroxylated triple helical protein, each of said first, second and product-encoding nucleotide sequences being operably linked to promoter
10 sequences, and

culturing said yeast host cell under conditions suitable to achieve expression of said first, second and product-encoding nucleotide sequences to thereby produce said hydroxylated triple helical protein; wherein said method is characterised in that the step of introducing the first,
15 second and product-encoding nucleotide sequences results in the said first, second and product-encoding nucleotide sequences, together with their respective operably linked promoter sequences, being borne on one or more replicable DNA molecules that are stably retained and segregated by said yeast host cell during said step of culturing.

20

2. A method according to claim 1, wherein the product-encoding nucleotide sequence(s) is/are nucleotide sequence(s) encoding a natural collagen or fragment thereof.

25 3. A method according to claim 2, wherein the product-encoding nucleotide sequence(s) is/are selected from COL1A1, COL1A2, COL2A1 and COL3A1 and fragments.

4. A method according to claim 3, wherein the product-encoding
30 nucleotide sequence(s) is COL3A1.

5. A method according to claim 1, wherein the product-encoding nucleotide sequence(s) is/are a nucleotide sequence(s) encoding a synthetic polypeptide(s) or peptide(s) of the general formula: $(A)_l-(B)_m-(\text{Gly X Y})_n-(C)_o-$
35 $(D)_p$, in which Gly is glycine, X and Y represent the same or different amino

acids, the identities of which may vary from Gly X Y triplet to Gly X Y triplet but wherein Y must be \geq one proline, A and D are polypeptide or peptide domains which may or may not include triple helical forming (Gly X Y)_n repeating sequences, B and C are intervening sequences which do not contain triple helical forming (Gly X Y)_n repeating sequences, n is in the range of 2 to 1500 and l, m, o and p are each independently selected from 0 and 1.

6. A method according to any one of the preceding claims, wherein the first and second nucleotide sequences are expressed from a bidirectional promoter sequence.

7. A method according to claim 6, wherein the bidirectional promoter sequence is the yeast GAL1-10 promoter sequence.

8. A method according to any one of the preceding claims, wherein the first and second nucleotide sequences are of avian or mammalian origin.

9. A method according to claims 8, wherein the first and second nucleotide sequences are of human origin.

10. A method according to any one of the preceding claims, wherein the second and product-encoding nucleotide sequences encode secretion signals such that expressed P4H and product polypeptide(s) or peptide(s) are secreted.

11. A method according to any one of the preceding claims, wherein the first, second and product-encoding nucleotide sequences are introduced to the yeast host cell such that they are present on one or more vector(s) including a CEN sequence(s).

12. A method according to any one of the preceding claims, wherein the first, second and product-encoding sequences are introduced to the yeast host cell such that they are present on one or more vector(s) including a CEN sequence(s) and one or two high copy number vector(s).

13. A method according to claim 11 or 12, wherein the one or more vector(s) including a CEN sequence(s) are selected from YAC vectors.
14. A method according to claim 12 or 13, wherein the one or two high copy number vector(s) are selected from YE_p plasmids.
15. A method according to claim 11, wherein the first, second and product-encoding nucleotide sequences are present on a single YAC vector.
- 10 16. A method according to any one of the preceding claims, wherein the yeast host cell is selected from the genus *Kluyveromyces*, *Saccharomyces*, *Schizosaccharomyces*, *Yarrowia* and *Pichia*.
- 15 17. A yeast host cell capable of producing a hydroxylated triple helical protein, said yeast host cell including a first nucleotide sequence encoding P4H α subunit, a second nucleotide sequence encoding P4H β subunit and one or more product-encoding nucleotide sequences which encode(s) a polypeptide(s) or peptide(s) which, when hydroxylated, form the said hydroxylated triple helical protein, each of said first, second and product-encoding nucleotide sequences being operably linked to promoter sequences, and wherein said first, second and product-encoding nucleotide sequences, together with their respective operably linked promoter sequences, are borne on one or more replicable DNA molecules that are stably retained and segregated by said yeast host cell.
- 20 25 18. A yeast host cell according to claim 17, wherein the product-encoding nucleotide sequence(s) is/are nucleotide sequence(s) encoding a natural collagen or fragment thereof.
- 30 19. A yeast host cell according to claim 18, wherein the product-encoding nucleotide sequence(s) is/are selected from COL1A1, COL1A2, COL2A1 and COL3A1 and fragments.
- 35 20. A yeast host cell according to claim 19, wherein the product-encoding nucleotide sequence(s) is COL3A1.

21. A yeast host cell according to claim 17, wherein the product-encoding nucleotide sequence(s) is/are a nucleotide sequence(s) encoding a synthetic polypeptide(s) or peptide(s) of the general formula: $(A)_l(B)_m-(Gly\ X\ Y)_n-(C)_o-(D)_p$, in which Gly is glycine, X and Y represent the same or different amino acids, the identities of which may vary from Gly X Y triplet to Gly X Y triplet but wherein Y must be \geq one proline, A and D are polypeptide or peptide domains which may or may not include triple helical forming $(Gly\ X\ Y)_n$ repeating sequences, B and C are intervening sequences which do not contain triple helical $(Gly\ X\ Y)_n$ repeating sequences, n is in the range of 2 to 1500 and l, m, o and p are each selected from 0 and 1.
22. A yeast host cell according to any one of claims 17 to 21, wherein the first and second nucleotide sequences are expressed from a bidirectional promoter sequence.
23. A yeast host cell according to claim 22, wherein the bidirectional promoter sequence is the yeast GAL1-10 promoter sequence.
24. A yeast host cell according to any one of claims 17 to 23, wherein the first and second nucleotide sequences are of avian or mammalian origin.
25. A yeast host cell according to claim 24, wherein the first and second nucleotide sequences are of human origin.
26. A yeast host cell according to any one of claims 17 to 25, wherein the second and product-encoding nucleotide sequences encode secretion signals such that expressed P4H and product polypeptide(s) or peptide(s) are secreted.
27. A yeast host cell according to any one of the claims 17 to 26, wherein the first, second and product-encoding nucleotide sequences are introduced to the yeast host cell such that they are present on one or more vector(s) including a CEN sequence(s).
28. A yeast host cell according to any one of claims 17 to 26, wherein the first, second and product-encoding sequences are introduced to the yeast

host cell such that they are present on one or more vector(s) including a CEN sequence(s) and one or two high copy number vector(s).

29. A yeast host cell according to claim 27 or 28, wherein the one or
5 more vector(s) including a CEN sequence(s) are selected from YAC vectors.
30. A yeast host cell according to claim 28 or 29, wherein the one or two
high copy number plasmid(s) are selected from YEp plasmids.
- 10 31. A yeast host cell according to claim 27, wherein the first, second and
product-encoding nucleotide sequences are present on a single YAC vector.
32. A yeast host cell according to any one of claims 17 to 31, wherein the
yeast host cell is selected from the genus *Kluveromyces*, *Saccharomyces*,
15 *Schizosaccharomyces*, *Yarrowia* and *Pichia*.
33. A triple helical protein produced in accordance with the method of
any one of claims 1 to 16.
- 20 34. A biomaterial or therapeutic product comprising a triple helical
protein produced in accordance with the method of any one of claims 1 to 16.

FIGURE 1




Figure 2

```

1   CCAGGCCCAC TTGGGATTGC TGGGATCACT GGAGCACGGG GTCTTGCAGG ACCACCAGGC
61  ATGCCAGGTC CTAGGGGAAG CCCTGGCCCT CAGGGTGTCA AGGGTGAAAG TGGGAAACCA
121 GGAGCTAACG GTCTCAGTGG AGAACGTGGT CCCCTGGAC CCCAGGGTCT TCCTGGTCTG
181 GCTGGTACAG CTGGTGAACC TGGAAGAGAT GGAAACCCTG GATCAGATGG TCTTCCAGGT
241 CGAGATGGAT CTCCTGGTGG CAAGGGTGAT CGTGGTGAAA ATGGCTCTCC TGGTGCCCTT
301 GGCGCTCCTG GTCATCCAGG CCCACCTGGT CCTGTCGGTC CAGCTGGAAA GAGTGGTGAC
361 AGAGGAGAAA GTGGCCCTGC TGGCCCTGCT GGTGCTCCCG GTCCTGCTGG TTCCCGAGGT
421 GCTCCTGGTC CTCAAGGCC ACCTGGTGAC AAAGGTGAAA CAGGTGAACG TGGAGCTGCT
481 GGCATCAAAG GACATCGAGG ATTCCCTGGT AATCCAGGTG CCCAGGTTC TCCAGGCCCT
541 GCTGGTCAGC AGGGTGCAAT CGGCAGTCCA GGACCTGCAG GCCCCAGAGG ACCTGTTGGA
601 CCCAGTGGAC CTCCTGGCAA AGATGGAACC AGTGGACATC CAGGTCCCAT TGGACCACCA
661 GGGCCTCGAG GTAACAGAGG TGAAAGAGGA TCTGAGGGCT CCCAGGCCA CCCAGGGCAA
721 CCAGGCCCTC CTGGACCTCC TGGTGCCCTT GGTCTTGTCT GCGGTGGTGT TGGAGCCGCT
781 GCCATTGCTG GGATTGGAGG TGAAAAAGCT GGCGGTTTTG CCCCGTATTA TGGACCTGAA
841 CCAATGGATT TCAAAATCAA CACCGATGAG ATTATCACTT CACTCAAGTC TGTTAATGGA
901 CAAATAGAAA GCCTCATTAG TCCTGATGGT TCTCGTAAAA ACCCCGCTAG AAATGCAGA
961 GACCTGAAAT TCTGCCATCC TGAACCTAAG ACTGGAGAAT ACTGGGTCGA CCCTAACCAG
1021 GGATGCAAAT TGGATGCTAT CAAGGTATTC TGTAATATGG AAATGGGGA AACATGCATA
1081 AGTGCCAATC CTTTGAATGT TCCACGGAAA CACTGGTGGA CAGATTCTAG TGCTGAGAAG
1141 AAACACGTTT GGTGGGAGA GTCCATCGAT GGTGGTTTTT AGTTTAGCTA CGGCAATCCT
1201 GAACTTCCTG AAGATGTCCT TGATGTGCAG CTGGCATTCC CTCGACTTCT CTCCAGCCGA
1261 GCTTCCCAGA ACATCACATA TCACTGCAAA AATAGCATTG CATACATGGA TCAGGCCAGT
1321 GGAAATGTAA AGAAGGCCCT GAAGCTGATG GGGTCAAATG AAGGTGAATT CAAGGCTGAA
1381 GGAAATAGCA AATTCACCTA CACAGTTCTG GAGGATGGTT GCACGAAACA CACTGGGGAA
1441 TGGAGCAAAA CAGTCTTTGA ATATCGAACA CGCAAGGCTG TGAGACTACC TATTGTAGAT
1501 ATTGCACCCT ATGACATTGG TGGTCCTGAT CAAGAATTTG GTGTGGACGT TGGCCCTGTT
1561 TGCTTTTTAT AA

```




FIGURE 3

KEY: S, signal peptide; N-PRO, N-terminal propeptide T, telopeptide;
C-PRO, C-terminal propeptide; kbp, kilobase pairs; bp, base pairs.

4/8

FIGURE 4




FIGURE 5

5/8





FIGURE 6

6/8



7/8

FIGURE 7




Figure 8

EcoRI
NcoI
1 G AATTCCATG GGTGCTCCAG GTGCTCCAGG TGGTAAGGGT GACGCTGGTG CTCCAGGTGA
N S M G A P G A P G G K G D A G A P G E

61 AAGAGGTCCA CCAGGTTTGG CTGGTGCTCC AGGTTTGAGA GGTGGTGCTG GTCCACCAGG
R G P P G L A G A P G L R G G A G P P G

Bsp120I
121 TCCAGAAGGT GGTAAGGGTG CTGCTGGTCC ACCAGGTCCA CCAGGTGGGC CCGGTGGTAA
P E G G K G A A G P P G P P G G P G G K

181 GGGTGACGCT GGTGCTCCAG GTGAAAGAGG TCCACCAGGT TTGGCTGGTG CTCCAGGTTT
G D A G A P G E R G P P G L A G A P G L

241 GAGAGGTGGT GCTGGTCCAC CAGGTCCAGA AGGTGGTAAG GGTGCTGCTG GTCCACCAGG
R G G A G P P G P E G G K G A A G P P G

BssHII
301 TCCACCAGGT GCGCGCGGTG GTAAGGGTGA CGCTGGTGCT CCAGGTGAAA GAGGTCCACC
P P G A R G G K G D A G A P G E R G P P

361 AGGTTTGGCT GGTGCTCCAG GTTTGAGAGG TGGTGCTGGT CCACCAGGTC CAGAAGGTGG
G L A G A P G L R G G A G P P G P E G G

421 TAAGGGTGCT GCTGGTCCAC CAGGTCCACC AGGTCCACCA GGTCCACCAG GTTGTGTGTTG
K G A A G P P G P P G P P G P P G C C G

XhoI SacII NheI
481 TCTCGAGGGT CCGCGGGGCT AGC
L E G P R G -

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/AU 97/00721

| | | |
|---|---|---|
| A. CLASSIFICATION OF SUBJECT MATTER | | |
| Int Cl ⁶ C12N 15/12, 15/81, 15/53; C07K 14/78; A61K 38/39 | | |
| According to International Patent Classification (IPC) or to both national classification and IPC | | |
| B. FIELDS SEARCHED | | |
| Minimum documentation searched (classification system followed by classification symbols) I/C C12N 15/12 | | |
| Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched | | |
| Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) MEDLINE) CHEM ABS) Collagen/procollagen, hydroxy(lase), triple heli., recombinant, S9028-06-2 WPAT) | | |
| | | |
| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| X | Lamberg et al. "Characterisation of Human Type III Collagen....." J. Biol. Chem. May 1997. 271(20). 11988-11995. Whole document | 1-34 |
| P,X | US 5 593 859 (Thos Jefferson University) OPI 14 Jan 1997, EPD 11 Aug 1994 pp 2-3, 5, example 8. | 1-34 |
| Y | JP 08023979 A (Terumo Corp) OPI 30 Jan 1996 EPD 15 Jul 1994. Abstract only. | 1-34 |
| <input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex | | |
| * Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family | | |
| Date of the actual completion of the international search | | Date of mailing of the international search report 08 DEC 1997 |
| Name and mailing address of the ISA/AU AUSTRALIAN INDUSTRIAL PROPERTY ORGANISATION PO BOX 200 WODEN ACT 2606 AUSTRALIA Facsimile No.: (02) 6285 3929 | | Authorized officer GILLIAN ALLEN Telephone No.: (02) 6283 2266 |

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/AU 97/00721

| C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT | | |
|--|---|-----------------------|
| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| Y, P | WO 97/14431 (Collagen Corporation). OPI 24 Apr 1997. EPD 20 Oct 1995. Whole document | 1-34 |
| Y | Tomita et al. "Synthesis of Recombinant human pro. α (III) chains..." Biochem J. 1995. 312. 847-853. | 1-10 |
| Y | Veijola et al "Cloning, Baculovirus Expression and Characterisation of the α Subunit of Prolyl 4-Hydroxylase...." 1994. 269(43). 26746-53 | 1-10 |
| Y | Armstrong et al "Ratlysyl hydroxylase...." Biochim Biophys Acta. 1995. 1264. 93-102 | 1-10 |
| Y | Krol et al. "The Expression of a Functional Secreted Human Lysyl Hydroxylase....." J. Invest. Dermatol. Jan 1996. 106(1). 11-16 | 1-10 |
| Y | Helaakoksi et al. "Cloning, Baculovirus Expression, and Characterisation of a Second Mouse Prolyl Hydroxylase...." Proc Nat Acad Sci USA. May 1995. 92. 4427-31 | 1-10 |
| Y | Vuori et al. "Characterisation of human prolyl 4-hydroxylase...." Proc Nat Acad Sci USA. 1992. 89. 7467-7470 | 1-10 |
| A | Bulleid et al "Type III procollagen assembly...." Biochem J. 1996. 317. 195-202 | |

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.
PCT/AU 97/00721

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

| Patent Document Cited in Search Report | | Patent Family Member | | | |
|--|-----------|----------------------|-----------|----|----------|
| US | 5 593 859 | AU | 30555/92 | EP | 625048 |
| | | US | 5 405 757 | WO | 93/07889 |
| JP | 08023979 | NONE | | | |
| WO | 97/14431 | AU | 74504/96 | | |
| END OF ANNEX | | | | | |

THIS PAGE BLANK (USPTO)